Alicia Dunajcik
Research Subjects
Alicia Dunajcik has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Adam MacNeil
Centers for Disease Control and Prevention (CDC), COVID-19 Response Team, Atlanta, Georgia, United States of America
1 shared publicationAmy Esler
1 shared publication- Andrea Salinas
Louisiana Department of Health, New Orleans, Louisiana, United States of America
1 shared publication Angela M. Thompson-Paul
1 shared publicationAnn M Powers
Centers for Disease Control and Prevention (CDC), COVID-19 Response Team, Atlanta, Georgia, United States of America
1 shared publicationAnna Krueger
Maine Center for Disease Control and Prevention, Augusta, Maine, United States of America
1 shared publication
Latest Publications
- 17 November 2026
- Published by Elsevier in Research in Developmental Disabilities
- Vol. 179
Early intervention in children with fragile X syndrome: Prevalence, timing, and family perception
- 17 November 2026
- Published by Elsevier in Research in Developmental Disabilities
- Vol. 179
Early intervention in children with fragile X syndrome: Prevalence, timing, and family perception
- Open Access
- 29 March 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (3) , e0001252
Travel history among persons infected with SARS-CoV-2 variants of concern in the United States, December 2020—February 2021
The first three SARS-CoV-2 phylogenetic lineages classified as variants of concern (VOCs) in the United States (U.S.) from December 15, 2020 to February 28, 2021, Alpha (B.1.1.7), Beta (B.1.351), and Gamma (P.1) lineages, were initially detected internationally. This investigation examined available travel history of coronavirus disease 2019 (COVID-19) cases reported in the U.S. in whom laboratory testing showed one of these initial VOCs. Travel history, demographics, and health outcomes for a convenience sample of persons infected with a SARS-CoV-2 VOC from December 15, 2020 through February 28, 2021 were provided by 35 state and city health departments, and proportion reporting travel was calculated. Of 1,761 confirmed VOC cases analyzed, 1,368 had available data on travel history. Of those with data on travel history, 1,168 (85%) reported no travel preceding laboratory confirmation of SARS-CoV-2 and only 105 (8%) reported international travel during the 30 days preceding a positive SARS-CoV-2 test or symptom onset. International travel was reported by 92/1,304 (7%) of persons infected with the Alpha variant, 7/55 (22%) with Beta, and 5/9 (56%) with Gamma. Of the first three SARS-CoV-2 lineages designated as VOCs in the U.S., international travel was common only among the few Gamma cases. Most persons infected with Alpha and Beta variant reported no travel history, therefore, community transmission of these VOCs was likely common in the U.S. by March 2021. These findings underscore the importance of global surveillance using whole genome sequencing to detect and inform mitigation strategies for emerging SARS-CoV-2 VOCs.
- 29 March 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (3) , e0001252
Open AccessTravel history among persons infected with SARS-CoV-2 variants of concern in the United States, December 2020—February 2021
The first three SARS-CoV-2 phylogenetic lineages classified as variants of concern (VOCs) in the United States (U.S.) from December 15, 2020 to February 28, 2021, Alpha (B.1.1.7), Beta (B.1.351), and Gamma (P.1) lineages, were initially detected internationally. This investigation examined available travel history of coronavirus disease 2019 (COVID-19) cases reported in the U.S. in whom laboratory testing showed one of these initial VOCs. Travel history, demographics, and health outcomes for a convenience sample of persons infected with a SARS-CoV-2 VOC from December 15, 2020 through February 28, 2021 were provided by 35 state and city health departments, and proportion reporting travel was calculated. Of 1,761 confirmed VOC cases analyzed, 1,368 had available data on travel history. Of those with data on travel history, 1,168 (85%) reported no travel preceding laboratory confirmation of SARS-CoV-2 and only 105 (8%) reported international travel during the 30 days preceding a positive SARS-CoV-2 test or symptom onset. International travel was reported by 92/1,304 (7%) of persons infected with the Alpha variant, 7/55 (22%) with Beta, and 5/9 (56%) with Gamma. Of the first three SARS-CoV-2 lineages designated as VOCs in the U.S., international travel was common only among the few Gamma cases. Most persons infected with Alpha and Beta variant reported no travel history, therefore, community transmission of these VOCs was likely common in the U.S. by March 2021. These findings underscore the importance of global surveillance using whole genome sequencing to detect and inform mitigation strategies for emerging SARS-CoV-2 VOCs.